NU7441 (KU-57788): Benchmark ATP-Competitive DNA-PK Inhibitor for DNA Repair and Oncology Research

Executive Summary: NU7441 (KU-57788) is a highly potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), displaying an IC₅₀ of 13–14 nM and a K_i of 0.65 nM under standard in vitro kinase assay conditions (25°C, Tris buffer) [APExBIO]. The compound is ATP-competitive, demonstrates minimal inhibition of related kinases ATM and ATR at concentrations up to 100 μM, and exhibits substantially weaker activity against mTOR (IC₅₀ = 1.7 μM) and PI3K (IC₅₀ = 5 μM) (Miao et al., 2023). NU7441 sensitizes multiple cancer cell lines to DNA damaging agents, leading to cell cycle arrest and enhanced cytotoxicity. In vivo, 10 mg/kg intraperitoneal dosing doubles the efficacy of etoposide phosphate in SW620 xenograft models. APExBIO supplies NU7441 (A8315) as a research-grade tool compound for precise DNA damage response and oncology workflows.

Biological Rationale

DNA-dependent protein kinase (DNA-PK) is a core component of the non-homologous end joining (NHEJ) pathway, essential for repair of DNA double-strand breaks (DSBs) in mammalian cells (Miao et al., 2023). Overexpression or hyperactivation of DNA-PK correlates with tumor resistance to DNA-damaging therapies and poor prognosis in several cancers, including gastric cancer. Inhibiting DNA-PK disrupts DSB repair, increasing sensitivity to ionizing radiation and genotoxic chemotherapies. The PRKDC gene encodes DNA-PKcs, the catalytic subunit targeted by NU7441. Recent studies show that PRKDC is regulated by the hsa_circ_0136666/miR-375 axis, modulating immune escape via PD-L1 phosphorylation (Miao et al., 2023). Thus, DNA-PK inhibition is a mechanistically rational approach to both sensitize tumors and modulate the tumor microenvironment.

Mechanism of Action of NU7441 (KU-57788)

NU7441 is an ATP-competitive, small-molecule inhibitor that binds the catalytic site of DNA-PKcs. It exhibits high affinity (K_i = 0.65 nM) and selectivity, displacing ATP from the active site and blocking kinase activity [APExBIO]. Unlike pan-kinase inhibitors, NU7441 shows minimal cross-inhibition of ATM and ATR at up to 100 μM, concentrations 10,000-fold above its DNA-PK IC₅₀. It has only modest activity against mTOR and PI3K (IC₅₀ = 1.7 μM and 5 μM, respectively), supporting its utility in dissecting DNA-PK-specific pathways. By inhibiting DNA-PK, NU7441 impairs NHEJ-mediated DSB repair, leading to accumulation of DNA lesions, activation of cell cycle checkpoints (notably G1 arrest), and increased apoptosis in response to DNA damage. Additionally, NU7441 indirectly enhances antitumor immunity by limiting PD-L1 phosphorylation and stability, as shown in models where hsa_circ_0136666/miR-375/PRKDC axis is active (Miao et al., 2023).

Evidence & Benchmarks

• NU7441 (KU-57788) inhibits DNA-PK with an IC₅₀ of 13–14 nM and a K_i of 0.65 nM in cell-free kinase assays (Tris buffer, 25°C) (APExBIO).
• Minimal inhibition of ATM and ATR is observed at concentrations as high as 100 μM, confirming high selectivity (Miao et al., 2023).
• In HeLa, LoVo, and SW620 cell lines, NU7441 enhances cytotoxicity of etoposide and ionizing radiation; cell viability is reduced by >50% compared to DNA-damaging agent alone in G1-arrested populations (Miao et al., 2023).
• In SW620 xenograft mice, 10 mg/kg intraperitoneal NU7441 plus etoposide phosphate doubles antitumor efficacy versus etoposide alone (tumor volume and survival endpoints) (Miao et al., 2023).
• NU7441 is insoluble in water and ethanol, but dissolves in DMSO at concentrations ≥4.13 mg/mL for use in cell-based and in vivo assays (APExBIO).
• Recent studies implicate PRKDC (DNA-PKcs) in immune checkpoint regulation via the hsa_circ_0136666/miR-375 axis, highlighting additional roles for NU7441 in immuno-oncology research (Miao et al., 2023).

For further context, see "NU7441 (KU-57788): Selective DNA-PK Inhibitor for Precision DNA Repair Studies", which details the compound's selectivity profile; this article updates those findings with new data on immune escape and in vivo efficacy. For a focus on workflow integration, "NU7441 (KU-57788): Scenario-Based Solutions for DNA Repair and Oncology Research" provides practical tips that are further contextualized here by recent immuno-oncology evidence.

Applications, Limits & Misconceptions

NU7441 is validated in DNA repair research, oncology workflows, and cell cycle arrest assays. It is used to:

• Sensitize tumor cells to DNA-damaging agents (e.g., etoposide, ionizing radiation).
• Dissect DNA damage response signaling, specifically NHEJ versus homologous recombination (HR) pathways.
• Probe PI3K/Akt/mTOR signaling with minimal off-target interference at recommended concentrations (<1 μM).
• Study immune evasion mechanisms via the PRKDC/PD-L1 axis in immune-competent models.

Common Pitfalls or Misconceptions

• NU7441 is not a pan-PI3K or pan-mTOR inhibitor; activity against these kinases requires concentrations ≥1.7 μM (mTOR) and ≥5 μM (PI3K), above typical working doses.
• It does not efficiently inhibit ATM/ATR even at high concentrations; results from ATM/ATR-dependent pathways should not be attributed to NU7441 action.
• The compound is insoluble in water and ethanol; improper solubilization can result in precipitation or loss of activity.
• Long-term storage of solutions is discouraged; freshly prepared DMSO solutions yield most reliable results.
• Cell cycle arrest effects are most pronounced in G1; S-phase or G2/M effects may require co-treatment with additional agents.

Workflow Integration & Parameters

APExBIO's NU7441 (A8315) is supplied as a powder, recommended to be dissolved in DMSO at ≥4.13 mg/mL. Store at -20°C, protect from light, and avoid repeated freeze-thaw cycles. In cell-based assays, working concentrations range from 10 nM to 1 μM, with treatment durations of 24–72 hours depending on endpoint. For in vivo xenograft models, 10 mg/kg intraperitoneal dosing is standard. Confirm DNA-PK inhibition by monitoring γ-H2AX foci (immunofluorescence) and cell cycle phase distribution (flow cytometry). For immune checkpoint studies, assess PD-L1 phosphorylation and CD8+ T cell infiltration as described in Miao et al. (2023).

For troubleshooting and advanced applications (e.g., synthetic lethality, combination screens), see "NU7441: A Selective DNA-PK Inhibitor Empowering DNA Repair and Oncology Research", which this article extends by adding immuno-oncology benchmarks and refined protocol recommendations.

Conclusion & Outlook

NU7441 (KU-57788) is a gold-standard, ATP-competitive, selective DNA-PK inhibitor, enabling precise studies of DNA damage response, cell cycle regulation, and immune escape in cancer biology. Its nanomolar potency and high selectivity minimize off-target effects, supporting robust and reproducible research outcomes. New evidence underscores NU7441's utility in immune checkpoint modulation and combination therapies. APExBIO's A8315 kit supports workflows from basic DNA repair to advanced immuno-oncology research. Ongoing advances in synthetic lethality and immune-targeted therapies continue to expand the relevance of NU7441 in precision oncology.